| Title |
Infrequent mutation of ATBF1 in human breast cancer
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, August 2006
|
| DOI | 10.1007/s00432-006-0148-y |
| Pubmed ID | |
| Authors |
Xiaodong Sun, Yingfa Zhou, Kristen B. Otto, Mingrong Wang, Ceshi Chen, Wei Zhou, Krithika Subramanian, Paula M. Vertino, Jin-Tang Dong |
| Abstract |
Deletion at chromosome 16q is frequent in prostate and breast cancers, suggesting the existence of one or more tumor suppressor genes in 16q. Recently, the transcription factor ATBF1 at 16q22 was identified as a strong candidate tumor suppressor gene in prostate cancer, and loss of ATBF1 expression was associated with poorer prognosis in breast cancer. In the present study, we examined mutation, expression, and promoter methylation of ATBF1 in 32 breast cancer cell lines. Only 2 of the 32 cancer cell lines had mutations, although 18 nucleotide polymorphisms were detected. In addition, 24 of 32 (75%) cancer cell lines had reduced ATBF1 mRNA levels, yet promoter methylation was not involved in gene silencing. These findings suggest that ATBF1 plays a role in breast cancer through transcriptional downregulation rather than mutations. |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 43% |
| Student > Bachelor | 2 | 14% |
| Other | 1 | 7% |
| Student > Master | 1 | 7% |
| Researcher | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 1 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 6 | 43% |
| Biochemistry, Genetics and Molecular Biology | 4 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Medicine and Dentistry | 1 | 7% |
| Unknown | 2 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2018.
All research outputs
#7,855,444
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#601
of 2,632 outputs
Outputs of similar age
#23,832
of 67,960 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#5
of 11 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 67,960 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.